| pubmed-article:15135291 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0125090 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0024204 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0879266 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:15135291 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:15135291 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15135291 | pubmed:dateCreated | 2004-5-11 | lld:pubmed |
| pubmed-article:15135291 | pubmed:abstractText | Reduced expression of CD62L can identify tumor-specific T cells in lymph nodes draining murine tumors. Here, we examined whether this strategy could isolate tumor-specific T cells from vaccinated patients. Tumor vaccine-draining lymph node (TVDLN) T cells of seven patients were separated into populations with reduced (CD62LLow) or high levels of CD62L (CD62LHigh). Effector T cells generated from CD62LLow cells maintained or enriched the autologous tumor-specific type 1 cytokine response compared to unseparated TVDLN T cells in four of four patients showing tumor-specific cytokine secretion. Interestingly, effector T cells generated from CD62LLow or CD62LHigh TVDLN were polarized towards a dominant type 1 or type 2 cytokine profile, respectively. For CD62LLow T cells the type 1 cytokine profile appeared determined prior to culture. Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy. | lld:pubmed |
| pubmed-article:15135291 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15135291 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15135291 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15135291 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15135291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15135291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15135291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15135291 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15135291 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15135291 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15135291 | pubmed:issn | 0008-8749 | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:RomeroPedroP | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:UrbaWalter... | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:HuHong-MingHM | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:FoxBernard... | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:MeijerSybren... | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:DolsAnnemieke... | lld:pubmed |
| pubmed-article:15135291 | pubmed:author | pubmed-author:ChuYiweiY | lld:pubmed |
| pubmed-article:15135291 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15135291 | pubmed:volume | 227 | lld:pubmed |
| pubmed-article:15135291 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15135291 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15135291 | pubmed:pagination | 93-102 | lld:pubmed |
| pubmed-article:15135291 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:meshHeading | pubmed-meshheading:15135291... | lld:pubmed |
| pubmed-article:15135291 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15135291 | pubmed:articleTitle | Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. | lld:pubmed |
| pubmed-article:15135291 | pubmed:affiliation | Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA. | lld:pubmed |
| pubmed-article:15135291 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15135291 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15135291 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
